MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) is positioning its artificial intelligence-powered voice analysis technology as a scalable alternative to traditional drug and alcohol testing methods that require biological samples. In a recent appearance on the TechMediaWire Podcast, CEO Justin Hanka detailed the company's plans to commercialize the technology, which uses non-invasive speech assessment to detect intoxication indicators associated with alcohol and drug use.
According to Hanka, MindBio has built prediction models using more than 50 million data points collected through years of clinical research. This extensive dataset enables the AI to identify intoxication markers with high accuracy simply by analyzing a person's voice. The technology is being developed for enterprise deployment, combining proprietary software with Edge-AI kiosks that can deliver assessments in less than three seconds. The company expects to begin live workplace testing during the second quarter of 2026.
The potential applications span multiple safety-sensitive industries, including mining, aviation, construction, and law enforcement. For these sectors, where impairment can pose significant safety risks, MindBio's technology could offer a quicker, less intrusive alternative to breathalyzers, blood tests, or urine samples. The ability to test frequently and on-site without requiring specialized collection equipment could also reduce operational disruptions and costs.
Beyond workplace impairment detection, management sees broader opportunities for AI-driven voice analytics as a diagnostic tool for identifying physiological and neurological conditions. This suggests that the underlying technology could eventually be adapted for medical applications, such as screening for certain diseases or monitoring patient health over time.
MindBio's approach aligns with a growing trend toward non-invasive health monitoring and the use of AI in diagnostics. If successful, the technology could reshape how companies approach workplace safety testing, potentially making it more routine and less stigmatizing. However, the company must navigate regulatory hurdles and prove that its voice analysis models are reliable across diverse populations and conditions before widespread adoption is possible.
For more information about MindBio Therapeutics and its voice analysis technology, visit the company's newsroom at https://ibn.fm/MBQIF. The full TechMediaWire podcast interview can be accessed at https://ibn.fm/HJarm.
